References
- Calabro-Jones P M, Aguiler J A, Ward J. F., et al. Uptake of WR-2721 derivatives by cells in culture: Identification of the transported form of the drug. Cancer Res 1988; 48: 3634–3640
- Valeriote F, Tolen S. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 1982; 42: 4330–4331
- Wasserman T H, Phillips T L, Ross G, Kane L J. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trials 1981; 4: 3–6
- Glover D, Glick J H, Weiler C., et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987; 5(4)574–578
- Glover D, Glick J H, Weiler C., et al. WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial. J Clin Oncol 1986; 4(4)584–588
- Constine L S, Zagars G, Rubin P, Kligerman M. Protection by WR-2721 of human bone marrow function following irradiation. Int I Radial Oncol Biol Phys 1986; 12: 1505–1508